Here are the 10-Q quarterly reports from Rocket Pharmaceuticals, Inc. Warrant (RCKTW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RCKTW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RCKTW filings page.
Rocket Pharmaceuticals, Inc. reported a sharp swing to profitability for the quarter ended June 30, 2026, driven by monetizing its Rare Pediatric Disease Priority Review Voucher. Net income was $123.2 million versus a net loss of $68.9 million a year earlier, primarily reflecting a $178.2 million gain on the PRV sale for $180 million.
Operating performance remained loss-making but more efficient. For the quarter, research and development expense fell to $29.5 million from $42.7 million, and general and administrative expense declined to $17.4 million from $25.0 million, with no new restructuring charges. Six‑month net income was $75.6 million versus a $130.3 million loss in 2025.
Liquidity improved significantly: cash, cash equivalents and investments totaled $283.7 million at June 30, 2026, up from $188.9 million at year‑end 2025, supporting management’s view that existing resources can fund operations into the second quarter of 2028. KRESLADI™ received FDA accelerated approval in March 2026, but the company has not yet generated product revenue and continues to invest in launch activities and its cardiovascular genetic medicines pipeline. The company also disclosed ongoing shareholder and derivative litigation related to prior Danon disease trial communications.